Ocular TherapeutixTM Announces Plans to Proceed with an NDA Submission for OTX-DP for Treatment of Post-Surgical Ocular Pain Indication; Reports First Quarter 2015 Financial Results

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 6/22/2026

1. SPCX
2. NVDA
3. ACN
4. USO
5. DFTX
6. GOOGL
7. APGE
8. MU
9. IBM
10. HOOD

Go back to Ocular TherapeutixTM Announces Plans to Proceed with an NDA Submission for OTX-DP for Treatment of Post-Surgical Ocular Pain Indication; Reports First Quarter 2015 Financial Results

Ocular Therapeutix (OCUL) Tops Q1 EPS by 4c; Sees DEXTENZA NDA Submission in H215

May 15, 2015 6:47 AM EDT

Ocular Therapeutix (NASDAQ: OCUL) reported Q1 EPS of ($0.35), $0.04 better than the analyst estimate of ($0.39).

Clinical Update for DEXTENZA for the Treatment of Post-Surgical Ocular Inflammation and Pain

Following a Pre-NDA Clinical meeting held with FDA in April 2015, Ocular Therapeutix is charting... More